All In MedTech

Device Trial Radar · NCT07390890

DSLT for Reducing Medication in Glaucoma

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Jan 26, 2027

Study completion Jan 26, 2027

Sponsor

Lead sponsor
The Eye Institute of West FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sengi
First posted
Feb 5, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Conditions

  • Primary Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Voyager DSLTDevice

    Voyager DSLT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)Time frame: 6 months post-DSLT treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Eye Institute of West Florida

    Largo, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.